Themenstarter
- Beitritt
- 28.10.08
- Beiträge
- 922
Ganz interessant. Werde die Tage auch noch übersetzen. Leider fehlt mir immoment die Zeit.
Gruß
Phil
Author:Krone CA, Elmer GW, Ely JT, Fudenberg HH, Thoreson J.
Title: Does gastrointestinal Candida albicans prevent ubiquinone absorption?
Source: Med Hypotheses 2001 Nov;57(5):570-2 .
Journal Title: Medical Hypotheses.
Abstract:
Ubiquinones (coenzyme Qs, (CoQ)) are essential for oxidative phosphorylation in yeasts and humans, although the isomers present in each are different. The human coenzyme Q, CoQ10, is administered orally for the treatment of heart disease and other disorders. Some patients, however, require much higher doses than others to attain a therapeutic CoQ10 blood level. We propose that one possible explanation for this variability is Candida colonization of the GI tract. Many common medical treatments including antibiotics and anti-hyperchlorhydric agents increase the risk of GI tract Candida colonization. Subsequent uptake and utilization of supplemental CoQ10 by the yeast could diminish availability for the human subject. Data from a patient and an in vitro pilot study using two pathogenic strains of C. albicans support this hypothesis. If C. albicans in the GI tract can hinder availability and interfere with therapeutic effects of CoQ10, it could be of clinical significance for large numbers of patients.
Gruß
Phil
Author:Krone CA, Elmer GW, Ely JT, Fudenberg HH, Thoreson J.
Title: Does gastrointestinal Candida albicans prevent ubiquinone absorption?
Source: Med Hypotheses 2001 Nov;57(5):570-2 .
Journal Title: Medical Hypotheses.
Abstract:
Ubiquinones (coenzyme Qs, (CoQ)) are essential for oxidative phosphorylation in yeasts and humans, although the isomers present in each are different. The human coenzyme Q, CoQ10, is administered orally for the treatment of heart disease and other disorders. Some patients, however, require much higher doses than others to attain a therapeutic CoQ10 blood level. We propose that one possible explanation for this variability is Candida colonization of the GI tract. Many common medical treatments including antibiotics and anti-hyperchlorhydric agents increase the risk of GI tract Candida colonization. Subsequent uptake and utilization of supplemental CoQ10 by the yeast could diminish availability for the human subject. Data from a patient and an in vitro pilot study using two pathogenic strains of C. albicans support this hypothesis. If C. albicans in the GI tract can hinder availability and interfere with therapeutic effects of CoQ10, it could be of clinical significance for large numbers of patients.
